Is BDSX or PIII more profitable?

P3 Health Partners has a net margin of -8.57% compared to Biodesix's net margin of -33.26%. P3 Health Partners' return on equity of 0.00% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -33.26% -2,101.40% -35.65% P3 Health Partners -8.57% N/A -19.99%

Does the media refer more to BDSX or PIII?

In the previous week, Biodesix had 2 more articles in the media than P3 Health Partners. MarketBeat recorded 4 mentions for Biodesix and 2 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.67 beat Biodesix's score of 0.58 indicating that P3 Health Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive P3 Health Partners 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PIII or LFMD more profitable?

LifeMD has a net margin of 2.37% compared to P3 Health Partners' net margin of -8.57%. P3 Health Partners' return on equity of 0.00% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets P3 Health Partners -8.57% N/A -19.99% LifeMD 2.37% -150.88% -22.59%

Does the media refer more to PIII or LFMD?

In the previous week, P3 Health Partners had 1 more articles in the media than LifeMD. MarketBeat recorded 2 mentions for P3 Health Partners and 1 mentions for LifeMD. P3 Health Partners' average media sentiment score of 0.67 beat LifeMD's score of 0.00 indicating that P3 Health Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment P3 Health Partners 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LifeMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is XGN or PIII more profitable?

P3 Health Partners has a net margin of -8.57% compared to Exagen's net margin of -29.49%. P3 Health Partners' return on equity of 0.00% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -29.49% -94.37% -28.96% P3 Health Partners -8.57% N/A -19.99%

Does the media favor XGN or PIII?

In the previous week, Exagen had 2 more articles in the media than P3 Health Partners. MarketBeat recorded 4 mentions for Exagen and 2 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.67 beat Exagen's score of 0.26 indicating that P3 Health Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral P3 Health Partners 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BNR or PIII?

P3 Health Partners has a consensus target price of $14.00, suggesting a potential upside of 39.72%. Given P3 Health Partners' stronger consensus rating and higher possible upside, analysts plainly believe P3 Health Partners is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 P3 Health Partners 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PARK or PIII more profitable?

Park Dental Partners has a net margin of 0.00% compared to P3 Health Partners' net margin of -8.57%. Company Net Margins Return on Equity Return on Assets Park Dental Partners N/A N/A N/A P3 Health Partners -8.57% N/A -19.99%

P3 Health Partners (PIII) Competitors

$10.02 +0.19 (+1.93%)

Closing price 04:00 PM Eastern

Extended Trading

$10.38 +0.36 (+3.54%)

As of 07:34 PM Eastern

Compare

PIII vs. BDSX, LFMD, XGN, BNR, and PARK

Should you buy P3 Health Partners stock or one of its competitors? MarketBeat compares P3 Health Partners with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with P3 Health Partners include Biodesix (BDSX), LifeMD (LFMD), Exagen (XGN), Burning Rock Biotech (BNR), and Park Dental Partners (PARK).

How does P3 Health Partners compare to Biodesix?

Biodesix (NASDAQ:BDSX) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Biodesix has higher earnings, but lower revenue than P3 Health Partners. Biodesix is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	2.58	-$35.26M	-$4.06	N/A
P3 Health Partners	$1.46B	0.05	-$147.95M	-$38.60	N/A

Biodesix presently has a consensus target price of $28.33, indicating a potential upside of 28.61%. P3 Health Partners has a consensus target price of $14.00, indicating a potential upside of 39.72%. Given P3 Health Partners' higher probable upside, analysts clearly believe P3 Health Partners is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Biodesix had 2 more articles in the media than P3 Health Partners. MarketBeat recorded 4 mentions for Biodesix and 2 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.67 beat Biodesix's score of 0.58 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
P3 Health Partners	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biodesix has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

P3 Health Partners has a net margin of -8.57% compared to Biodesix's net margin of -33.26%. P3 Health Partners' return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
P3 Health Partners	-8.57%	N/A	-19.99%

21.0% of Biodesix shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 23.2% of Biodesix shares are owned by insiders. Comparatively, 10.9% of P3 Health Partners shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Biodesix beats P3 Health Partners on 9 of the 17 factors compared between the two stocks.

How does P3 Health Partners compare to LifeMD?

P3 Health Partners (NASDAQ:PIII) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

In the previous week, P3 Health Partners had 1 more articles in the media than LifeMD. MarketBeat recorded 2 mentions for P3 Health Partners and 1 mentions for LifeMD. P3 Health Partners' average media sentiment score of 0.67 beat LifeMD's score of 0.00 indicating that P3 Health Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
P3 Health Partners	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

P3 Health Partners has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, LifeMD has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

LifeMD has lower revenue, but higher earnings than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.05	-$147.95M	-$38.60	N/A
LifeMD	$194.05M	0.93	$14.35M	$0.05	74.60

LifeMD has a net margin of 2.37% compared to P3 Health Partners' net margin of -8.57%. P3 Health Partners' return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-8.57%	N/A	-19.99%
LifeMD	2.37%	-150.88%	-22.59%

7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 10.9% of P3 Health Partners shares are held by insiders. Comparatively, 17.2% of LifeMD shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

P3 Health Partners currently has a consensus target price of $14.00, indicating a potential upside of 39.72%. LifeMD has a consensus target price of $9.14, indicating a potential upside of 145.12%. Given LifeMD's stronger consensus rating and higher possible upside, analysts plainly believe LifeMD is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

LifeMD beats P3 Health Partners on 11 of the 16 factors compared between the two stocks.

How does P3 Health Partners compare to Exagen?

Exagen (NASDAQ:XGN) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

In the previous week, Exagen had 2 more articles in the media than P3 Health Partners. MarketBeat recorded 4 mentions for Exagen and 2 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.67 beat Exagen's score of 0.26 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
P3 Health Partners	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exagen has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Exagen has higher earnings, but lower revenue than P3 Health Partners. Exagen is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.70	-$19.95M	-$0.89	N/A
P3 Health Partners	$1.46B	0.05	-$147.95M	-$38.60	N/A

P3 Health Partners has a net margin of -8.57% compared to Exagen's net margin of -29.49%. P3 Health Partners' return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
P3 Health Partners	-8.57%	N/A	-19.99%

75.3% of Exagen shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 10.4% of Exagen shares are owned by company insiders. Comparatively, 10.9% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Exagen presently has a consensus target price of $9.00, suggesting a potential upside of 92.31%. P3 Health Partners has a consensus target price of $14.00, suggesting a potential upside of 39.72%. Given Exagen's stronger consensus rating and higher possible upside, research analysts plainly believe Exagen is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Exagen beats P3 Health Partners on 10 of the 17 factors compared between the two stocks.

How does P3 Health Partners compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

In the previous week, P3 Health Partners had 2 more articles in the media than Burning Rock Biotech. MarketBeat recorded 2 mentions for P3 Health Partners and 0 mentions for Burning Rock Biotech. P3 Health Partners' average media sentiment score of 0.67 beat Burning Rock Biotech's score of 0.00 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Burning Rock Biotech	Neutral
P3 Health Partners	Positive

P3 Health Partners has a net margin of -8.57% compared to Burning Rock Biotech's net margin of -11.57%. P3 Health Partners' return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
P3 Health Partners	-8.57%	N/A	-19.99%

Burning Rock Biotech has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

P3 Health Partners has a consensus target price of $14.00, suggesting a potential upside of 39.72%. Given P3 Health Partners' stronger consensus rating and higher possible upside, analysts plainly believe P3 Health Partners is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 10.9% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Burning Rock Biotech has higher earnings, but lower revenue than P3 Health Partners. Burning Rock Biotech is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.21	-$7.92M	-$0.82	N/A
P3 Health Partners	$1.46B	0.05	-$147.95M	-$38.60	N/A

Summary

P3 Health Partners beats Burning Rock Biotech on 10 of the 16 factors compared between the two stocks.

How does P3 Health Partners compare to Park Dental Partners?

Park Dental Partners (NASDAQ:PARK) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Park Dental Partners has a net margin of 0.00% compared to P3 Health Partners' net margin of -8.57%.

Company	Net Margins	Return on Equity	Return on Assets
Park Dental Partners	N/A	N/A	N/A
P3 Health Partners	-8.57%	N/A	-19.99%

7.8% of P3 Health Partners shares are held by institutional investors. 10.6% of Park Dental Partners shares are held by company insiders. Comparatively, 10.9% of P3 Health Partners shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Park Dental Partners has higher earnings, but lower revenue than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Park Dental Partners	$244.49M	0.34	-$360K	$0.74	25.01
P3 Health Partners	$1.46B	0.05	-$147.95M	-$38.60	N/A

In the previous week, P3 Health Partners had 2 more articles in the media than Park Dental Partners. MarketBeat recorded 2 mentions for P3 Health Partners and 0 mentions for Park Dental Partners. P3 Health Partners' average media sentiment score of 0.67 beat Park Dental Partners' score of 0.00 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Park Dental Partners	Neutral
P3 Health Partners	Positive

Park Dental Partners presently has a consensus price target of $21.75, suggesting a potential upside of 17.50%. P3 Health Partners has a consensus price target of $14.00, suggesting a potential upside of 39.72%. Given P3 Health Partners' higher probable upside, analysts clearly believe P3 Health Partners is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Park Dental Partners beats P3 Health Partners on 8 of the 15 factors compared between the two stocks.

Get P3 Health Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PIII vs. The Competition

Export

Metric	P3 Health Partners	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$71.22M	$9.93B	$6.86B	$12.45B
Dividend Yield	N/A	2.54%	2.60%	10.03%
P/E Ratio	-0.26	25.38	280.72	24.99
Price / Sales	0.05	4.92	588.04	90.94
Price / Cash	N/A	26.44	28.64	34.82
Price / Book	-0.46	5.22	11.02	6.21
Net Income	-$147.95M	$312.25M	$3.48B	$347.49M
7 Day Performance	-4.39%	-0.20%	0.56%	0.89%
1 Month Performance	-11.87%	-0.89%	-4.14%	-3.60%
1 Year Performance	36.33%	27.08%	63.23%	20.46%

P3 Health Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PIII P3 Health Partners	2.5337 of 5 stars	$10.02 +1.9%	$14.00 +39.7%	+33.7%	$71.22M	$1.46B	N/A	500	News Coverage Upcoming Earnings
BDSX Biodesix	3.3729 of 5 stars	$21.03 -5.4%	$28.33 +34.7%	+191.9%	$230.11M	$88.50M	N/A	220	Upcoming Earnings
LFMD LifeMD	2.2051 of 5 stars	$3.84 -0.8%	$9.14 +138.1%	-64.8%	$187.16M	$194.05M	76.82	230	Upcoming Earnings
XGN Exagen	2.9143 of 5 stars	$4.45 +1.1%	$9.11 +104.7%	-47.5%	$106.30M	$66.57M	N/A	220	News Coverage Upcoming Earnings
BNR Burning Rock Biotech	0.638 of 5 stars	$8.98 -4.5%	N/A	+54.9%	$98.87M	$77.16M	N/A	1,390	Positive News Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PIII) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

P3 Health Partners (PIII) Competitors

PIII vs. BDSX, LFMD, XGN, BNR, and PARK

How does P3 Health Partners compare to Biodesix?

Summary

How does P3 Health Partners compare to LifeMD?

Summary

How does P3 Health Partners compare to Exagen?

Summary

How does P3 Health Partners compare to Burning Rock Biotech?

Summary

How does P3 Health Partners compare to Park Dental Partners?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIII vs. The Competition

P3 Health Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

P3 Health Partners (PIII) Competitors

PIII vs. BDSX, LFMD, XGN, BNR, and PARK

How does P3 Health Partners compare to Biodesix?

Which has stronger valuation and earnings, BDSX or PIII?

Do analysts rate BDSX or PIII?

Does the media refer more to BDSX or PIII?

Which has more risk & volatility, BDSX or PIII?

Is BDSX or PIII more profitable?

Do institutionals & insiders believe in BDSX or PIII?

Summary

How does P3 Health Partners compare to LifeMD?

Does the media refer more to PIII or LFMD?

Which has more risk & volatility, PIII or LFMD?

Which has higher valuation and earnings, PIII or LFMD?

Is PIII or LFMD more profitable?

Do insiders and institutionals hold more shares of PIII or LFMD?

Do analysts prefer PIII or LFMD?

Summary

How does P3 Health Partners compare to Exagen?

Does the media favor XGN or PIII?

Which has more volatility & risk, XGN or PIII?

Which has stronger earnings and valuation, XGN or PIII?

Is XGN or PIII more profitable?

Do insiders and institutionals hold more shares of XGN or PIII?

Do analysts prefer XGN or PIII?

Summary

How does P3 Health Partners compare to Burning Rock Biotech?

Does the media favor BNR or PIII?

Is BNR or PIII more profitable?

Which has more volatility & risk, BNR or PIII?

Do analysts prefer BNR or PIII?

Do insiders and institutionals hold more shares of BNR or PIII?

Which has stronger earnings and valuation, BNR or PIII?

Summary

How does P3 Health Partners compare to Park Dental Partners?

Is PARK or PIII more profitable?

Do insiders and institutionals have more ownership in PARK or PIII?

Which has better earnings and valuation, PARK or PIII?

Does the media favor PARK or PIII?

Do analysts recommend PARK or PIII?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIII vs. The Competition

P3 Health Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools